Diagnostic procedures in the follow-up of patients affected by MEN type 2.
D019797:3-Iodobenzylguanidine; D000310:Adrenal Gland Neoplasms / Q000097:blood / Q000175:diagnosis*; D014408:Biomarkers, Tumor / Q000097:blood*; D002116:Calcitonin / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000097:blood; D018276:Carcinoma, Medullary / Q000097:blood / Q000175:diagnosis*; D053379:Chromogranin A; D002864:Chromogranins / Q000097:blood; D005500:Follow-Up Studies; D006801:Humans; D006961:Hyperparathyroidism / Q000175:diagnosis; D008279:Magnetic Resonance Imaging; D018813:Multiple Endocrine Neoplasia Type 2a / Q000097:blood / Q000175:diagnosis*; D018814:Multiple Endocrine Neoplasia Type 2b / Q000097:blood / Q000175:diagnosis*; D010673:Pheochromocytoma / Q000097:blood / Q000175:diagnosis*; D000090063:Proto-Oncogene Mas; D019275:Radiopharmaceuticals; D013964:Thyroid Neoplasms / Q000097:blood / Q000175:diagnosis*; D014055:Tomography, Emission-Computed; D014057:Tomography, X-Ray Computed
D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D053379:Chromogranin A; D002864:Chromogranins; C000715470:MAS1 protein, human; D000090063:Proto-Oncogene Mas; D019275:Radiopharmaceuticals; D019797:3-Iodobenzylguanidine; D002116:Calcitonin